

RECEIVED  
CENTRAL FAX CENTER


- 2 -

DEC 01 2006

We claim:

1. (Previously presented) A compound of formula

**IIIc:**



**IIIc**

or a pharmaceutically acceptable salt thereof, wherein:

$R^x$  is  $T-R^3$  or  $L-Z-R^3$ ;

$R^y$  is independently selected from  $T-R^8$  or  $L-Z-R^3$ , wherein  $R^8$  is selected from an optionally substituted group selected from  $C_{1-6}$  aliphatic,  $C_{6-10}$  aryl, a heteroaryl ring having 5-10 ring atoms, a heterocyclyl ring having 5-10 ring atoms, -halo, -OR,  $-C(=O)R$ ,  $-CO_2R$ ,  $-COCOR$ ,  $-COCH_2COR$ ,  $-NO_2$ ,  $-CN$ ,  $-S(O)R$ ,  $-S(O)_2R$ ,  $-SR$ ,  $-N(R^4)_2$ ,  $-CON(R^7)_2$ ,  $-SO_2N(R^7)_2$ ,  $-OC(=O)R$ ,  $-N(R^7)COR$ ,  $-N(R^7)CO_2(C_{1-6} \text{ aliphatic})$ ,  $-N(R^4)N(R^4)_2$ ,  $-C=NN(R^4)_2$ ,  $-C=N-OR$ ,  $-N(R^7)CON(R^7)_2$ ,  $-N(R^7)SO_2N(R^7)_2$ ,  $-N(R^4)SO_2R$ , or  $-OC(=O)N(R^7)_2$ ;

$R^1$  is  $T-(\text{Ring D})$ ;

Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein Ring D is substituted at any substitutable ring carbon by oxo,

- 3 -

T-R<sup>5</sup>, or V-Z-R<sup>5</sup>, and at any substitutable ring nitrogen by -R<sup>4</sup>;

T is a valence bond or a C<sub>1-4</sub> alkylidene chain;

Z is a C<sub>1-4</sub> alkylidene chain;

L is -O-, -S-, -SO-, -SO<sub>2</sub>-, -N(R<sup>6</sup>)SO<sub>2</sub>-, -SO<sub>2</sub>N(R<sup>6</sup>)-,  
 -N(R<sup>6</sup>)-, -CO-, -CO<sub>2</sub>-, -N(R<sup>6</sup>)CO-, -N(R<sup>6</sup>)C(O)O-,  
 -N(R<sup>6</sup>)CON(R<sup>6</sup>)-, -N(R<sup>6</sup>)SO<sub>2</sub>N(R<sup>6</sup>)-, -N(R<sup>6</sup>)N(R<sup>6</sup>)-,  
 -C(O)N(R<sup>6</sup>)-, -OC(O)N(R<sup>6</sup>)-, -C(R<sup>6</sup>)<sub>2</sub>O-, -C(R<sup>6</sup>)<sub>2</sub>S-,  
 -C(R<sup>6</sup>)<sub>2</sub>SO-, -C(R<sup>6</sup>)<sub>2</sub>SO<sub>2</sub>-, -C(R<sup>6</sup>)<sub>2</sub>SO<sub>2</sub>N(R<sup>6</sup>)-, -C(R<sup>6</sup>)<sub>2</sub>N(R<sup>6</sup>)-,  
 -C(R<sup>6</sup>)<sub>2</sub>N(R<sup>6</sup>)C(O)-, -C(R<sup>6</sup>)<sub>2</sub>N(R<sup>6</sup>)C(O)O-, -C(R<sup>6</sup>)=NN(R<sup>6</sup>)-,  
 -C(R<sup>6</sup>)=N-O-, -C(R<sup>6</sup>)<sub>2</sub>N(R<sup>6</sup>)N(R<sup>6</sup>)-, -C(R<sup>6</sup>)<sub>2</sub>N(R<sup>6</sup>)SO<sub>2</sub>N(R<sup>6</sup>)-, or  
 -C(R<sup>6</sup>)<sub>2</sub>N(R<sup>6</sup>)CON(R<sup>6</sup>)-;

R<sup>2</sup> and R<sup>2'</sup> are independently selected from -R, -T-W-R<sup>6</sup>, or  
 R<sup>2</sup> and R<sup>2'</sup> are taken together with their intervening  
 atoms to form a fused, 5-8 membered, unsaturated or  
 partially unsaturated, ring having 0-3 ring heteroatoms  
 selected from nitrogen, oxygen, or sulfur, wherein each  
 substitutable carbon on said fused ring formed by R<sup>2</sup>  
 and R<sup>2'</sup> is substituted by halo, oxo, -CN, -NO<sub>2</sub>, -R<sup>7</sup>, or  
 -V-R<sup>6</sup>, and any substitutable nitrogen on said ring  
 formed by R<sup>2</sup> and R<sup>2'</sup> is substituted by R<sup>4</sup>;

R<sup>3</sup> is selected from -R, -halo, -OR, -C(=O)R, -CO<sub>2</sub>R,  
 -COCOR, -COCH<sub>2</sub>COR, -NO<sub>2</sub>, -CN, -S(O)R, -S(O)<sub>2</sub>R, -SR,  
 -N(R<sup>4</sup>)<sub>2</sub>, -CON(R<sup>7</sup>)<sub>2</sub>, -SO<sub>2</sub>N(R<sup>7</sup>)<sub>2</sub>, -OC(=O)R, -N(R<sup>7</sup>)COR,  
 -N(R<sup>7</sup>)CO<sub>2</sub>(C<sub>1-6</sub> aliphatic), -N(R<sup>4</sup>)N(R<sup>4</sup>)<sub>2</sub>, -C=NN(R<sup>4</sup>)<sub>2</sub>,  
 -C=N-OR, -N(R<sup>7</sup>)CON(R<sup>7</sup>)<sub>2</sub>, -N(R<sup>7</sup>)SO<sub>2</sub>N(R<sup>7</sup>)<sub>2</sub>, -N(R<sup>4</sup>)SO<sub>2</sub>R, or  
 -OC(=O)N(R<sup>7</sup>)<sub>2</sub>;

each R is independently selected from hydrogen or an  
 optionally substituted group selected from C<sub>1-6</sub>  
 aliphatic, C<sub>6-10</sub> aryl, a heteroaryl ring having 5-10  
 ring atoms, or a heterocyclyl ring having 5-10 ring  
 atoms;

- 4 -

each  $R^4$  is independently selected from  $-R^7$ ,  $-\text{COR}^7$ ,  
 $-\text{CO}_2(\text{optionally substituted } \text{C}_{1-6} \text{ aliphatic})$ ,  $-\text{CON}(\text{R}^7)_2$ ,  
 or  $-\text{SO}_2\text{R}^7$ ;

each  $R^5$  is independently selected from  $-\text{R}$ , halo,  $-\text{OR}$ ,  
 $-\text{C}(=\text{O})\text{R}$ ,  $-\text{CO}_2\text{R}$ ,  $-\text{COCOR}$ ,  $-\text{NO}_2$ ,  $-\text{CN}$ ,  $-\text{S}(\text{O})\text{R}$ ,  $-\text{SO}_2\text{R}$ ,  $-\text{SR}$ ,  
 $-\text{N}(\text{R}^4)_2$ ,  $-\text{CON}(\text{R}^4)_2$ ,  $-\text{SO}_2\text{N}(\text{R}^4)_2$ ,  $-\text{OC}(=\text{O})\text{R}$ ,  $-\text{N}(\text{R}^4)\text{COR}$ ,  
 $-\text{N}(\text{R}^4)\text{CO}_2(\text{optionally substituted } \text{C}_{1-6} \text{ aliphatic})$ ,  
 $-\text{N}(\text{R}^4)\text{N}(\text{R}^4)_2$ ,  $-\text{C}=\text{NN}(\text{R}^4)_2$ ,  $-\text{C}=\text{N}-\text{OR}$ ,  $-\text{N}(\text{R}^4)\text{CON}(\text{R}^4)_2$ ,  
 $-\text{N}(\text{R}^4)\text{SO}_2\text{N}(\text{R}^4)_2$ ,  $-\text{N}(\text{R}^4)\text{SO}_2\text{R}$ , or  $-\text{OC}(=\text{O})\text{N}(\text{R}^4)_2$ ;

V is  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{SO}-$ ,  $-\text{SO}_2-$ ,  $-\text{N}(\text{R}^6)\text{SO}_2-$ ,  $-\text{SO}_2\text{N}(\text{R}^6)-$ ,  
 $-\text{N}(\text{R}^6)-$ ,  $-\text{CO}-$ ,  $-\text{CO}_2-$ ,  $-\text{N}(\text{R}^6)\text{CO}-$ ,  $-\text{N}(\text{R}^6)\text{C}(\text{O})\text{O}-$ ,  
 $-\text{N}(\text{R}^6)\text{CON}(\text{R}^6)-$ ,  $-\text{N}(\text{R}^6)\text{SO}_2\text{N}(\text{R}^6)-$ ,  $-\text{N}(\text{R}^6)\text{N}(\text{R}^6)-$ ,  
 $-\text{C}(\text{O})\text{N}(\text{R}^6)-$ ,  $-\text{OC}(\text{O})\text{N}(\text{R}^6)-$ ,  $-\text{C}(\text{R}^6)_2\text{O}-$ ,  $-\text{C}(\text{R}^6)_2\text{S}-$ ,  
 $-\text{C}(\text{R}^6)_2\text{SO}-$ ,  $-\text{C}(\text{R}^6)_2\text{SO}_2-$ ,  $-\text{C}(\text{R}^6)_2\text{SO}_2\text{N}(\text{R}^6)-$ ,  $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)-$ ,  
 $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)\text{C}(\text{O})-$ ,  $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)\text{C}(\text{O})\text{O}-$ ,  $-\text{C}(\text{R}^6)=\text{NN}(\text{R}^6)-$ ,  
 $-\text{C}(\text{R}^6)=\text{N}-\text{O}-$ ,  $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)\text{N}(\text{R}^6)-$ ,  $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)\text{SO}_2\text{N}(\text{R}^6)-$ , or  
 $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)\text{CON}(\text{R}^6)-$ ;

W is  $-\text{C}(\text{R}^6)_2\text{O}-$ ,  $-\text{C}(\text{R}^6)_2\text{S}-$ ,  $-\text{C}(\text{R}^6)_2\text{SO}-$ ,  $-\text{C}(\text{R}^6)_2\text{SO}_2-$ ,  
 $-\text{C}(\text{R}^6)_2\text{SO}_2\text{N}(\text{R}^6)-$ ,  $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)-$ ,  $-\text{CO}-$ ,  $-\text{CO}_2-$ ,  
 $-\text{C}(\text{R}^6)\text{OC}(\text{O})-$ ,  $-\text{C}(\text{R}^6)\text{OC}(\text{O})\text{N}(\text{R}^6)-$ ,  $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)\text{CO}-$ ,  
 $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)\text{C}(\text{O})\text{O}-$ ,  $-\text{C}(\text{R}^6)=\text{NN}(\text{R}^6)-$ ,  $-\text{C}(\text{R}^6)=\text{N}-\text{O}-$ ,  
 $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)\text{N}(\text{R}^6)-$ ,  $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)\text{SO}_2\text{N}(\text{R}^6)-$ ,  
 $-\text{C}(\text{R}^6)_2\text{N}(\text{R}^6)\text{CON}(\text{R}^6)-$ , or  $-\text{CON}(\text{R}^6)-$ ;

each  $R^6$  is independently selected from hydrogen or an  
 optionally substituted  $\text{C}_{1-4}$  aliphatic group, or two  $R^6$   
 groups on the same nitrogen atom are taken together  
 with the nitrogen atom to form a 5-6 membered  
 heterocyclyl or heteroaryl ring; and

each  $R^7$  is independently selected from hydrogen or an  
 optionally substituted  $\text{C}_{1-6}$  aliphatic group, or two  $R^7$   
 on the same nitrogen are taken together with the  
 nitrogen to form a 5-8 membered heterocyclyl or  
 heteroaryl ring.

- 5 -

2. (Previously presented) The compound according to claim 1, wherein said compound has one or more features selected from the group consisting of:

- (a)  $R^x$  is hydrogen, alkyl- or dialkylamino, acetamido, or a  $C_{1-4}$  aliphatic group;
- (b)  $R^y$  is  $T-R^8$  or  $L-Z-F^3$ , wherein T is a valence bond or a methylene and  $R^3$  is  $-R$ ,  $-N(R^4)_2$ , or  $-OR$  and  $R^8$  is an optionally substituted group selected from  $C_{1-6}$  aliphatic,  $C_{6-10}$  aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms,  $-N(R^4)_2$  or  $-OR$ ;
- (c)  $R^1$  is  $T-(\text{Ring D})$ , wherein T is a valence bond or a methylene unit;
- (d) Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
- (e)  $R^2$  is  $-R$  or  $-T-W-R^6$  and  $R^{2'}$  is hydrogen, or  $R^2$  and  $R^{2'}$  are taken together to form an optionally substituted benzo ring.

3. (Previously presented) The compound according to claim 2, wherein:

- (a)  $R^x$  is hydrogen, alkyl- or dialkylamino, acetamido, or a  $C_{1-4}$  aliphatic group;
- (b)  $R^y$  is  $T-R^8$  or  $L-Z-F^3$ , wherein T is a valence bond or a methylene and  $R^3$  is  $-R$ ,  $-N(R^4)_2$ , or  $-OR$  and  $R^8$  is an optionally substituted group selected from  $C_{1-6}$  aliphatic,  $C_{6-10}$  aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms,  $-N(R^4)_2$  or  $-OR$ ;
- (c)  $R^1$  is  $T-(\text{Ring D})$ , wherein T is a valence bond or a methylene unit;

- 6 -

- (d) Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
- (e)  $R^2$  is -R or -T-W- $R^6$  and  $R^{2'}$  is hydrogen, or  $R^2$  and  $R^{2'}$  are taken together to form an optionally substituted benzo ring.

4. (Previously presented) The compound according to claim 2, wherein said compound has one or more features selected from the group consisting of:

- (a)  $R^y$  is T- $R^8$  or L-Z- $R^3$  wherein T is a valence bond or a methylene and  $R^3$  and  $R^8$  are selected from -R, -OR, or -N( $R^4$ )<sub>2</sub>, wherein R is selected from C<sub>1-6</sub> aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;
- (b)  $R^1$  is T-(Ring D), wherein T is a valence bond;
- (c) Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
- (d)  $R^2$  is -R and  $R^{2'}$  is hydrogen, wherein R is selected from hydrogen, C<sub>1-6</sub> aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
- (e) L is -O-, -S-, or -N( $R^4$ )-.

5. (Previously presented) The compound according to claim 4, wherein:

- (a)  $R^y$  is T- $R^8$  or L-Z- $R^3$  wherein T is a valence bond or a methylene and  $R^3$  and  $R^8$  are selected from -R, -OR, or -N( $R^4$ )<sub>2</sub>, wherein R is selected from C<sub>1-6</sub> aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;
- (b)  $R^1$  is T-(Ring D), wherein T is a valence bond;
- (c) Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;

- 7 -

- (d)  $R^2$  is -R and  $R^{2'}$  is hydrogen, wherein R is selected from hydrogen,  $C_{1-6}$  aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
- (e) L is -O-, -S-, or -N( $R^4$ )-.

6. (Previously presented) The compound according to claim 4, wherein said compound has one or more features selected from the group consisting of:

- (a)  $R^x$  is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetimido;
- (b)  $R^y$  is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl;
- (c)  $R^1$  is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, -CN, -NO<sub>2</sub>, -N( $R^4$ )<sub>2</sub>, optionally substituted  $C_{1-6}$  aliphatic group, -OR, -CO<sub>2</sub>R, -CONH( $R^4$ ), -N( $R^4$ )COR, -N( $R^4$ )SO<sub>2</sub>R, -N( $R^6$ )COCH<sub>2</sub>CH<sub>2</sub>N( $R^4$ )<sub>2</sub>, or -N( $R^6$ )COCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>N( $R^4$ )<sub>2</sub>; and
- (d)  $R^2$  is hydrogen or a substituted or unsubstituted  $C_{1-6}$  aliphatic, and L is -O-, -S-, or -NH-.

7. (Original) The compound according to claim 6, wherein:

- 8 -

- (a) R<sup>x</sup> is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetimido;
- (b) R<sup>y</sup> is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl;
- (c) R<sup>1</sup> is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, -CN, -NO<sub>2</sub>, -N(R<sup>4</sup>)<sub>2</sub>, optionally substituted C<sub>1-6</sub> aliphatic group, -OR, -CO<sub>2</sub>R, -CONH(R<sup>4</sup>), -N(R<sup>4</sup>)COR, -N(R<sup>4</sup>)SO<sub>2</sub>R, -N(R<sup>6</sup>)COCH<sub>2</sub>CH<sub>2</sub>N(R<sup>4</sup>)<sub>2</sub>, or -N(R<sup>6</sup>)COCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>N(R<sup>4</sup>)<sub>2</sub>; and
- (d) R<sup>2</sup> is hydrogen or a substituted or unsubstituted C<sub>1-6</sub> aliphatic, and L is -O-, -S-, or -NH-.

8. (Original) A compound selected from the group consisting of:

- (5-Methyl-2H-pyrazol-3-yl)-(6-phenyl-2-phenylamino-pyrimidin-4-yl)-amine;
- (5-Cyclopropyl-2H-pyrazol-3-yl)-(6-phenyl-2-phenylamino-pyrimidin-4-yl)-amine;
- (5-Cyclopropyl-2H-pyrazol-3-yl)-[2-(3-methylphenylamino)-6-phenyl-pyrimidin-4-yl]-amine;
- [2-(4-cyanomethylphenylamino)-6-phenyl-pyrimidin-4-yl]- (5-cyclopropyl-2H-pyrazol-3-yl)-amine;
- (5-Cyclopropyl-2H-pyrazol-3-yl)-[6-phenyl-2-(pyridin-3-ylmethylamino)-pyrimidin-4-yl]-amine;

- 9 -

[2-(3-Chlorophenyl)amino-6-(3-nitrophenyl)-pyrimidin-4-yl]-(5-methyl-2H-pyrazol-3-yl)-amine;

[2-(3-Chlorophenyl)amino-6-(3,4,5-trimethoxyphenyl)-pyrimidin-4-yl]-(5-methyl-2H-pyrazol-3-yl)-amine;

(5-Methyl-2H-pyrazol-3-yl)-[2-(4-sulfamoylphenylamino)-6-(3,4,5-trimethoxyphenyl)-pyrimidin-4-yl]-amine;

[2-(4-Chlorophenyl)amino-6-methyl-pyrimidin-4-yl]-(5-(furan-2-yl)-2H-pyrazol-3-yl)-amine;

[2-(Benzimidazol-2-ylamino)-6-ethyl-pyrimidin-4-yl]-(5-methyl-2H-pyrazol-3-yl)-amine;

[2-(4-Chlorophenyl)amino-6-methyl-pyrimidin-4-yl]-(5-phenyl-2H-pyrazol-3-yl)-amine;

[2-(4-Chlorophenyl)amino-6-ethyl-pyrimidin-4-yl]-(5-methyl-2H-pyrazol-3-yl)-amine;

(5-tert-Butyl-2H-pyrazol-3-yl)-[2-(3-chlorophenyl)amino-6-(3-nitrophenyl)-pyrimidin-4-yl]-amine;

[2-(3-Chlorophenyl)amino-6-(3-nitrophenyl)-pyrimidin-4-yl]-(5-phenyl-2H-pyrazol-3-yl)-amine;

[5-(Furan-2-yl)-2H-pyrazol-3-yl]-(6-phenyl-2-phenylamino-pyrimidin-4-yl)-amine;

[2-(Benzimidazol-2-ylamino)-6-methyl-pyrimidin-4-yl]-(5-phenyl-2H-pyrazol-3-yl)-amine;

[2-(Benzimidazol-2-ylamino)-6-methyl-pyrimidin-4-yl]-(5-(Furan-2-yl)-2H-pyrazol-3-yl)-amine;

[2-(4-Chlorophenylamino)-6-methyl-pyrimidin-4-yl]-(5-methyl-2H-pyrazol-3-yl)-amine;

[2-(4-Chlorophenyl)amino-5,6-dimethyl-pyrimidin-4-yl]-(5-methyl-2H-pyrazol-3-yl)-amine;

(5,6-Dimethyl-2-phenylamino-pyrimidin-4-yl)-(5-methyl-2H-pyrazol-3-yl)-amine;

[2-(4-Chlorophenyl)amino-6-methoxymethyl-pyrimidin-4-yl]-(5-methyl-2H-pyrazol-3-yl)-amine;



- 10 -

[2-(Benzimidazol-2-ylamino)-6-methoxymethyl-pyrimidin-4-yl]-(5-methyl-2H-pyrazol-3-yl)-amine;

(6-Methoxymethyl-2-phenylamino-pyrimidin-4-yl)-(5-methyl-2H-pyrazol-3-yl)-amine;

(6-Methyl-2-phenylamino-pyrimidin-4-yl)-(5-methyl-2H-pyrazol-3-yl)-amine;

*N*<sup>4</sup>-(5-Cyclopropyl-1H-pyrazol-3-yl)-*N*<sup>2</sup>-(1H-indazol-5-yl)-6-methyl-pyrimidine-2,4-diamine; and

*N*<sup>2</sup>-Benzothiazol-6-yl-*N*<sup>4</sup>-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-pyrimidine-2,4-diamine.

9. (Original) A composition comprising a compound according to any one of claims 1-8; and a pharmaceutically acceptable carrier.

10. (Original) The composition according to claim 9, further comprising an additional therapeutic agent.

11. (Currently amended) A method of inhibiting Aurora-2, GSK-3, or Src activity in a biological sample selected from cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof comprising the step of contacting said biological sample with a compound according to any one of claims 1-8.

12-13. (Canceled)

14. (Previously presented) A method of treating melanoma, lymphoma, neuroblastoma, leukemia, or a cancer selected from colon, breast, lung, kidney, ovary, pancreatic, renal, CNS, cervical, prostate, and cancer of

- 11 -

the gastric tract, said method comprising the step of administering to said patient a composition according to any one of claims 1-8.

15. (Canceled)

16. (Previously presented) The method according to claim 14, wherein said method further comprises administering an additional therapeutic agent selected from a chemotherapeutic agent or anti-proliferative agent.

17. (Original) The method according to claim 16, wherein said additional therapeutic agent is a chemotherapeutic agent.

18-19. (Canceled)

20. (Previously presented) A method of treating diabetes and schizophrenia, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a composition according to claim 9.

21. (Canceled)

22. (Currently amended) The method according to claim ~~21~~20, wherein said disease is diabetes.

23-26. (Canceled)

27. (Currently amended) A method of treating ~~hypercalcemia, osteoporosis, osteoarthritis, colon~~

- 12 -

cancer, or ovarian cancer, ~~symptomatic treatment of bone metastasis, or Paget's disease~~, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a composition according to claim 9.